

# Eric Van Den Neste

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6150332/publications.pdf>

Version: 2024-02-01

40  
papers

714  
citations

567281

15  
h-index

552781

26  
g-index

40  
all docs

40  
docs citations

40  
times ranked

1278  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adult haemophagocytic lymphohistiocytosis: a review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 115, 205-213.	0.5	43
2	Bingâ€œNeel syndrome hidden by multiple sclerosis, a challenging overlay of diseases. <i>Acta Neurologica Belgica</i> , 2022, 122, 227-229.	1.1	0
3	Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?. <i>Leukemia and Lymphoma</i> , 2022, 63, 743-746.	1.3	5
4	Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. <i>Cancers</i> , 2022, 14, 1761.	3.7	0
5	Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 293-304.	2.0	21
6	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. <i>Blood</i> , 2021, 137, 3495-3506.	1.4	22
7	Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-3.	1.3	1
8	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4149-4155.	5.2	42
9	Improvement in progressive multifocal leukoencephalopathy after pembrolizumabâ€œinduced immune reconstruction inflammatory syndrome in a patient with follicular lymphoma. <i>EJHaem</i> , 2020, 1, 585-588.	1.0	2
10	Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 2531-2535.	7.2	20
11	Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. <i>Leukemia</i> , 2019, 33, 776-780.	7.2	16
12	Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies. <i>Leukemia and Lymphoma</i> , 2019, 60, 1043-1052.	1.3	1
13	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	1.4	130
14	A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. <i>Haematologica</i> , 2018, 103, 840-848.	3.5	45
15	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. <i>Transplantation</i> , 2018, 102, 1914-1923.	1.0	11
16	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 998-998.	1.4	19
17	A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untreated Follicular B-Cell Lymphoma in Need of Systemic Therapy. <i>Blood</i> , 2018, 132, 446-446.	1.4	2
18	Results from the Belgian mantle cell lymphoma registry. <i>Acta Clinica Belgica</i> , 2017, 72, 172-178.	1.2	3

#	ARTICLE	IF	CITATIONS
19	Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort study. <i>Psycho-Oncology</i> , 2017, 26, 2086-2093.	2.3	4
20	Chronic lymphocytic leukemia management in the elderly: let us not forget the patient "even on a busy day. <i>Leukemia and Lymphoma</i> , 2017, 58, 509-510.	1.3	0
21	Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. <i>American Journal of Hematology</i> , 2016, 91, E16-7.	4.1	13
22	A crucial role for ATR in the regulation of deoxycytidine kinase activity. <i>Biochemical Pharmacology</i> , 2016, 100, 40-50.	4.4	18
23	Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 328-334.	1.3	9
24	Endoscopic features of lymphoproliferative diseases. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1480-1481.	1.0	0
25	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , 2015, 126, 517-517.	1.4	2
26	Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 773-780.	1.3	69
27	Protein phosphatase 2A regulates deoxycytidine kinase activity via Ser74 dephosphorylation. <i>FEBS Letters</i> , 2014, 588, 727-732.	2.8	4
28	Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 581-591.	2.3	42
29	Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. <i>Haematologica</i> , 2013, 98, 1185-1195.	3.5	51
30	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. <i>Blood</i> , 2013, 122, 764-764.	1.4	8
31	Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma. <i>Blood</i> , 2013, 122, 87-87.	1.4	25
32	Updated Follow-Up In The CLL2007FMP Trial Supports The Non Superiority Of The Association Fludarabine-Cyclophosphamide (FC) Plus Campath Compared To FC Plus Rituximab and Points Out The Importance Of Minimal Residual Disease, By 6-Color Flow Cytometry Technique, On Progression Free Survival. <i>Blood</i> , 2013, 122, 2870-2870.	1.4	0
33	Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1445-1451.	1.3	7
34	Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. <i>Leukemia and Lymphoma</i> , 2012, 53, 362-370.	1.3	7
35	Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Aged > 65 years : Results of a Multicenter Trial (LLC 2007 SA) On Behalf of the French Goelams/Fcgcll-WM Intergroup. <i>Blood</i> , 2012, 120, 434-434.	1.4	12
36	First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy. <i>Blood</i> , 2012, 120, 57-57.	1.4	5

#	ARTICLE	IF	CITATIONS
37	First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,. Blood, 2011, 118, 4110-4110.	1.4	3
38	AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies. Expert Opinion on Investigational Drugs, 2010, 19, 571-578.	4.1	25
39	Acadesine for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase I/II Study. Blood, 2010, 116, 4625-4625.	1.4	0
40	Second Primary Tumors and Immune Phenomena After Fludarabine or 2-Chloro-2-Deoxy adenosine Treatment. Leukemia and Lymphoma, 2001, 40, 541-550.	1.3	27